Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/43154
Registro completo de metadados
Campo DCValorIdioma
dc.creatorDagotto, Gabriel-
dc.creatorYu, Jingyou-
dc.creatorBarouch, Dan H.-
dc.date.accessioned2020-09-22T17:45:05Z-
dc.date.available2020-09-22T17:45:05Z-
dc.date.issued2020-09-
dc.identifier.citationDAGOTTO, G.; YU, J.; BAROUCH, D. H. Approaches and challenges in SARS-CoV-2 vaccine development. Cell Host & Microbe, [S.l.], v. 28, n. 3, p. 364-370, Sept. 2020.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1931312820304558pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/43154-
dc.description.abstractThe explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.pt_BR
dc.languageen_USpt_BR
dc.publisherCell Presspt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceCell Host & Microbept_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectCOVID-19 - Vaccinept_BR
dc.titleApproaches and challenges in SARS-CoV-2 vaccine developmentpt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.